Pifithrin-α hydrobromide-武汉科斯坦生物科技有限公司

产品展厅

您当前的位置：网站首页 > 产品展厅 >Pifithrin-α hydrobromide

Pifithrin-α hydrobromide

英文名称：Pifithrin-α hydrobromide

品牌：Chemstan

产地：武汉

货号：CS-15484

cas：63208-82-2

价格： ￥698/支
发布日期： 2021-03-10
更新日期： 2025-09-29

发送咨询信息

产品详请

产地	武汉
品牌	Chemstan
货号	CS-15484
用途	科研
英文名称	Pifithrin-α hydrobromide
包装规格	5 mg
纯度	100%%
CAS编号	63208-82-2
别名	PFTα hydrobromide,?Pifithrin hydrobromide,?Pifithrin-α hydrobromide,?Pifithrin-α (PFTα) HBr,?PFTα
分子式	C16H18N2OS稨Br?
是否进口	否

Description

Pifithrin-α hydrobromide is a p53 inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an aryl hydrocarbon receptor (AhR) agonist.

IC₅₀ & Target

p53^[1]
AhR^[2]

In Vitro

Pifithrin-α (PFT-α) hydrobromideis a water-soluble compound that could suppress p53 protein transcription. Pifithrin-α can suppress glucose oxidase (GOX)-induced p53 protein increase in whole cell lysates, but cyclosporine A (CsA) fails to show such an inhibition effect. Notably, Pifithrin-α is able to block the GOX-induced Bcl-2 protein reduction. Similarly, it is Pifithrin-α rather than CsA that able to prevent the Bax increasing in whole cell lysates^[1]. Pifithrin-α inhibits p53-dependent apoptosis through an undetermined mechanism. Pifithrin-α also acts as an aryl hydrocarbon receptor (AhR) agonist and. Pifithrin-α is a potent AhR agonist as determined by its ability to bind the AhR, induce formation of its DNA binding complex, activate reporter activity, and up-regulate the classic AhR target gene CYP1A1^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

When the experiment is performed with Pifthirin-α (PFT-α) hydrobromide, a pharmacological p53 inhibitor, the percentage of annexin V-positive Foxe3^-/- SMCs decreases to WT levels. Pifithrin-α (2.2 mg/kg, i.p.) significantly reduces the incidence of aortic rupture and intramural hematomas in Foxe3^-/- mice that underwent transverse aortic constriction (TAC) (50% to 17%, P<0.05). After Pifthirin-α treatment, the mean diameter of the ascending aorta and the percentage of TUNEL-positive cells in the aortic media are also normalized to WT levels in surviving Foxe3^-/- animals (P<0.05)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

367.30

Formula

C??H??BrN?OS

CAS No.

63208-82-2

SMILES

N=C1SC2=C(CCCC2)N1CC(C3=CC=C(C)C=C3)=O.[H]Br

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (136.13 mM)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg

1 mM	2.7226 mL	13.6129 mL	27.2257 mL
5 mM	0.5445 mL	2.7226 mL	5.4451 mL
10 mM	0.2723 mL	1.3613 mL	2.7226 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (6.81 mM); Clear solution

*以上所有助溶剂都可在 MCE 网站选购。

References

[1]. Yu W, et al. Cyclosporine A Suppressed Glucose Oxidase Induced P53 Mitochondrial Translocation and Hepatic Cell Apoptosis through Blocking Mitochondrial Permeability Transition. Int J Biol Sci. 2016 Jan 1;12(2):198-209.

[2]. Hoagland MS, et al. The p53 Inhibitor Pifithrin-α Is a Potent Agonist of the Aryl Hydrocarbon Receptor. J Pharmacol Exp Ther. 2005 Aug;314(2):603-10.

[3]. Kuang SQ, et al. FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. J Clin Invest. 2016 Mar 1;126(3):948-61.